Keyphrases
High-risk Human Papillomavirus (HR-HPV)
100%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
69%
Head-and-neck Cancer
68%
Head-and-neck
57%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
38%
Overall Survival
33%
Squamous Cell Carcinoma of Head
32%
Nasopharyngeal Carcinoma
31%
Cetuximab
28%
Recurrent Metastatic
24%
Clinical Outcomes
23%
Chemoradiotherapy
22%
Transoral Robotic Surgery
21%
Recurrent or Metastatic
19%
Progression-free Survival
18%
HPV16
17%
Cancer Patients
16%
Viral
16%
Human Papillomavirus DNA
15%
HPV+
15%
Prognostic Significance
15%
Tumor Tissue
15%
Induction Chemotherapy
15%
Locoregional Control
15%
Metastatic Squamous Cell Carcinoma
15%
5-fluorouracil (5-FU)
14%
High Risk
14%
Locally Advanced
13%
Distant Control
12%
Reduced Dose
12%
Adjuvant Therapy
12%
HPV-related Oropharyngeal Cancer
12%
Adjuvant Radiation Therapy
11%
Extracapsular Extension
11%
Treatment Outcome
11%
Standard of Care
11%
Cisplatin
11%
Radiotherapy
10%
Re-irradiation
10%
Pembrolizumab
10%
Phase II Study
10%
Adenoid Cystic Carcinoma
10%
Circulating Tumor DNA (ctDNA)
10%
Adjuvant Radiotherapy
10%
Toxicity Profile
10%
Working Diagnosis
9%
Recurrent Disease
9%
Carboplatin
9%
Docetaxel
9%
Radiation Therapy
9%
Medicine and Dentistry
Oropharyngeal Cancer
84%
Wart Virus
83%
Neck
45%
Squamous Cell Carcinoma
39%
Overall Survival
32%
Radiation Therapy
31%
Head and Neck Squamous Cell Carcinoma
31%
Oropharynx Carcinoma
29%
Neoplasm
29%
Head and Neck Cancer
25%
Chemoradiotherapy
25%
Malignant Neoplasm
24%
Disease
23%
Recurrent Disease
22%
Robot-Assisted Surgery
21%
Cetuximab
21%
Oropharynx Squamous Cell Carcinoma
20%
Progression Free Survival
19%
Adjuvant Therapy
12%
Docetaxel
11%
Adjuvant Radiotherapy
11%
Thyroid Cancer
10%
Cylindroma
10%
Pembrolizumab
10%
Clinical Trial
9%
Contralateral
8%
Larynx
7%
Adjuvant Chemoradiotherapy
7%
Metastatic Carcinoma
7%
Patient Population
7%
Squamous Cell
7%
Personalized Medicine
7%
Cancer Cell
7%
Radioactive Iodine
7%
Tongue
6%
Arm
6%
Induction Chemotherapy
6%
Systemic Therapy
6%
Differentiated Thyroid Cancer
6%
Human Papillomavirus Type 16
6%
Lymph Node
6%
Positron Emission Tomography
6%
Hazard Ratio
6%
Survival Rate
5%
Proportional Hazards Model
5%
Prematurity
5%
Combination Chemotherapy
5%
Carboxymethyl Cellulose
5%
Polylysine
5%
Zoledronic Acid
5%
Pharmacology, Toxicology and Pharmaceutical Science
Human Papillomavirus
44%
Head and Neck Cancer
37%
Head and Neck Squamous Cell Carcinoma
36%
Squamous Cell Carcinoma
35%
Chemoradiation Therapy
33%
Oropharynx Cancer
33%
Overall Survival
31%
Disease
27%
Chemotherapy
25%
Cetuximab
23%
Neoplasm
18%
Oropharynx Carcinoma
18%
Recurrent Disease
17%
Malignant Neoplasm
16%
Fluorouracil
15%
Docetaxel
13%
Cisplatin
11%
Progression Free Survival
11%
Human Papillomavirus Type 16
10%
Pembrolizumab
10%
Oropharynx Squamous Cell Carcinoma
10%
Clinical Trial
8%
Tolerability
8%
Carboplatin
8%
Metastasis
7%
Taxane
6%
Comorbidity
6%
Hydroxycarbamide
6%
Mucosa Inflammation
5%
Prematurity
5%
Maximum Tolerated Dose
5%
Patient History of Chemotherapy
5%
Dovitinib
5%
Afatinib
5%
Trametinib
5%
Growth Factor Receptor
5%
Sorafenib
5%
Endothelial Cell Growth Factor
5%
Radioactive Iodine
5%
Thyroid Cancer
5%
Zoledronic Acid
5%
Colorectal Cancer
5%
Salivary Gland Carcinoma
5%
Epidermal Growth Factor Receptor Kinase Inhibitor
5%
Cancer Epidemiology
5%
Cabazitaxel
5%
Adenoid Cystic Carcinoma
5%
Fluorodeoxyglucose
5%
Obesity
5%
Metastatic Colorectal Cancer
5%